Key Takeaways GSK lifted its sales and earnings projections for the year, after a strong performance by its HIV and cancer drugs drove second-quarter sales higher. The British pharmaceutical firm said sales rose 13% year-over-year to 7.88 billion pounds ($10.12 billion), beating analysts' estimates. GSK said it expects sales growth between 7% and 9% this year, up from its prior forecast, but cut its vaccine sales outlook. GSK (GSK) lifted its sales and earnings projections for the year, after a strong perfo ...

GSK (GSK) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9%. A quarter ago, it was expected that this drug developer would post earnings of $0.94 per share when it actually produced earnings of $1.09, delivering a surprise of 15.96%.Over the last four quarters, the company has surpassed ...

Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companies Initial phase to identify and accelerate promising scientific concepts for further research starting in respiratory and immunology GSK and Flagship to jointly fund up to $150 million upfront LONDON and CAMBRIDGE, Mass., July 29, 2024 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have e ...

文章核心观点 - 公司即将发布第二季度财报 [1] - 公司近期业绩表现较好 [3][4] - 公司有望在本次财报中实现业绩超预期 [5][6] 公司业务表现 - 专科药物、疫苗和常规药物三大业务板块表现良好 [7] - 新产品如Arexvy、Cabenuva、Juluca、Dovato、Trelegy Ellipta和Shingrix销售强劲,抵消了老产品销售下滑 [8][9][10][11] - 肿瘤业务受益于Jemperli、Zejula和Ojjaara等新药销售增长 [12] 公司发展前景 - 公司剥离消费品业务后专注于药品研发 [20] - 公司预计2024年销售和利润将分别增长5-7%和9-11% [20] - 公司计划在2026年前推出20多个新产品/线延伸产品,其中10多个有潜力成为重磅产品 [22] - 公司通过收购等方式加强在肿瘤/血液学领域的布局 [22] 投资评级 - 公司股价近期表现低于行业和大盘 [14][15] - 公司估值相对行业较低,具有投资价值 [17][18] - 分析师对公司未来增长持乐观态度,建议长期投资者持有 [23]

GSK plc (GSK) announced that the European Medicines Agency (EMA) has accepted its marketing authorization application (MAA) seeking approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory multiple myeloma (RRMM) for review.The MAA seeks the approval of Blenrep in combination with J&J’s (JNJ) Velcade (bortezomib) plus dexamethasone (BorDex) or Bristol Myers’ Pomalyst (pomalidomide) plus dexamethasone (PomDex) for the myeloma indication in the EU. Per GSK, the advis ...

GSK, a multinational pharma company, scans as a bargain.GSK (GSK 0.59%), a global healthcare powerhouse, has been on a transformative journey since CEO Emma Walmsley took the helm in 2017. Despite its shares badly underperforming the S&P 500 under her first few years as CEO (see graph below), Walmsley's ambitious restructuring plan has achieved several key goals, including but not limited to higher profitability, dividend payments that align with free cash flows, and a more innovative culture that embraces ...

Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless of the ongoing economic conditions. In other words, demand for healthcare and medications tends to be “inelastic,” meaning that even if the costs of purchasing medications and healthcare services tick upward, demand is not likely to change substantively. This provides a stable revenue stream for pharmaceutical ...

GSK plc (GSK) boasts a diversified base and presence in different geographical areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug development. In July 2022, GSK de-merged its Consumer Healthcare segment into a standalone company. The independent Consumer Healthcare company was named Haleon (HLN) . Haleon was a consumer health joint venture, an over-the-counter medicines business, jointly created by GSK and partner Pfizer (PFE) in 2019. GSK has been regularly selling its stake i ...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the dosing of the first patient in GALAXIES Lung-301, a global, randomized, double-blind Phase 3 registrational clinical trial of belrestotug + dostarlimab versus placebo + pembrolizumab in patients with firstline advanc ...

GSK plc (GSK) announced that the European Medicines Agency (“EMA”) has accepted its application seeking approval for the expanded use of its cancer drug Jemperli (dostarlimab). The application is seeking approval for Jemperli plus chemotherapy to treat all adult patients with primary advanced or recurrent endometrial cancer.Pending review by the EMA’s Committee for Medicinal Products for Human Use, a decision from the European Commission is expected in the first half of 2025.Jemperli is currently approved f ...